Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Scientists propose new truncated process for developing COVID-19 vaccines

Agencies
Updated: May 21st, 2020, 18:44 IST
in Coronavirus, International, Sci-Tech
0
Vaccine
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Washington: Scientists have proposed a new truncated process for developing vaccines quickly during the COVID-19 pandemic. They want a fast start and many steps executed in parallel to curtail time in finding a proper vaccine. They say that in the present situation if prolonged processes are followed then it is not feasible to fight COVIDS-19.

Lengthy, expensive process

Researchers from the Coalition for Epidemic Preparedness Innovation (CEPI) said vaccine development is a lengthy, expensive process. There are high rates of attrition, typically taking multiple candidates. It takes and many years to produce a licensed therapeutic.

Also Read

trump

Trump calls on all NATO countries to stop buying Russian oil, threatens 50% to 100% tariffs on China

13 hours ago

US asks G7 countries to impose tariffs on countries purchasing oil from Russia

16 hours ago

CEPI in the United States is a foundation that finances independent research projects to develop vaccines against emerging infectious diseases.

Process of making vaccine

In an article, published in the ‘New England Journal of Medicine’, experts from CEPI said vaccine developers had an observation to make. They said scientists usually follow a linear sequence of steps, with multiple pauses for data analysis. Then comes the manufacturing-process checks due to the cost and high failure rates of the process.

However, with a quick start and phases executed in parallel the scientists believe the process can be fast-tracked. However, there are high financial risks involved. They said for some vaccine platforms which have yielded significant success in humans. So Phase I clinical trials may be able to proceed in parallel with testing in animal models.

Clinical trials

According to the researchers, an ideal platform for this new paradigm would support development from viral sequencing to clinical trials. The entire process will take less than 16 weeks.

Such a truncated process, they said, can demonstrate the successful and consistent activation of immune responses in humans. It will then be suitable for a large-scale manufacturing platform that is independent of the pathogen.

Ideal example

They cited an example also. They said Moderna’s mRNA-based SARS-CoV-2 candidate vaccine entered a Phase I clinical trial March 16. It was less than 10 weeks after the first genetic sequences were released.

The proposed paradigm, the scientists said, requires multiple activities to be conducted at financial risk. There is always the chance that the vaccine candidate will not be safe and the results effective.

Among those with the greatest potential for quick development are DNA- and RNA-based platforms, the researchers noted in the article. They explained that both these genetic material-based vaccines can be made quickly. This is because they do not require culture or fermentation, but instead use synthetic processes.

Other methods to quicken research

Among other ways of hastening the process, they said testing in a suitable animal model, and rigorous safety monitoring in clinical trials will be critical. The scientists also suggested that manufacturing steps could be scaled up to commercial levels before data on the trial’s outcomes are available. However, they cautioned that building manufacturing capacity can cost hundreds of millions of dollars.

Agencies

 

Tags: COVID-19DNA & RNAGeneticImmuneManufacturingscientistsvaccines
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Sibarama Khotei

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

Tabish Maaz

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Surya Sidhant Rath

December 12, 2019
#MyPaperBagChallenge

Amritansh Mishra

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Pratyasharani Ghibela

December 12, 2019
#MyPaperBagChallenge

Ipsita

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Manas Samanta

December 12, 2019
#MyPaperBagChallenge

Rajashree Pravati Mohanty

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Priyabrata Mohanty

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Archit Mohapatra

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Sitakanta Mohanty

December 12, 2019
#MyPaperBagChallenge

Archana Parida

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019

Archives

Editorial

Majoritarian Momentum

September 14, 2025

An American scholar has written a book in which he tries to explain China’s recent rise. Dan Wang’s thesis is...

Read moreDetails

CBI’s Glass House

September 13, 2025

India’s top anti-corruption watchdog, the CVC, has just delivered a stinging reality check to the CBI, and it’s not a...

Read moreDetails

Reviving 9/11 Spirit

Donald Trump
September 10, 2025

The memories of the deadly al-Qaeda strikes on 9/11 on iconic US building complexes are still alive even after several...

Read moreDetails

Evolving Nepal

Nepal
September 9, 2025

Violence erupted in Kathmandu 8 September as thousands of young Nepalese took to the streets and clashed with security forces,...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST